WO1999012576A3 - Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy - Google Patents

Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy Download PDF

Info

Publication number
WO1999012576A3
WO1999012576A3 PCT/US1998/019267 US9819267W WO9912576A3 WO 1999012576 A3 WO1999012576 A3 WO 1999012576A3 US 9819267 W US9819267 W US 9819267W WO 9912576 A3 WO9912576 A3 WO 9912576A3
Authority
WO
WIPO (PCT)
Prior art keywords
natriuretic peptide
atrial natriuretic
nucleic acid
acid encoding
tissue kallikrein
Prior art date
Application number
PCT/US1998/019267
Other languages
French (fr)
Other versions
WO1999012576A2 (en
Inventor
Lee Chao
Julie Chao
Original Assignee
Musc Found For Res Dev
Lee Chao
Julie Chao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev, Lee Chao, Julie Chao filed Critical Musc Found For Res Dev
Priority to AU94876/98A priority Critical patent/AU9487698A/en
Publication of WO1999012576A2 publication Critical patent/WO1999012576A2/en
Publication of WO1999012576A3 publication Critical patent/WO1999012576A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a method for treating a nonhypertension-associated renal disorder in a subject having a nonhypertension associated renal disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating a nonhypertension-associated renal disorder. Also provided is a method of treating a nonhypertension-associated cardiac disorder in a subject having a nonhypertension-associated cardiac disorder, comprising administering to the subject a nucleic acid encoding tissue kallikrein and/or a nucleic acid encoding atrial natriuretic peptide under conditions whereby the nucleic acid encoding tissue kallikrein and/or the nucleic acid encoding atrial natriuretic peptide is expressed in a cell in the subject, thereby treating the nonhypertension-associated cardiac disorder.
PCT/US1998/019267 1997-09-11 1998-09-11 Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy WO1999012576A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU94876/98A AU9487698A (en) 1997-09-11 1998-09-11 Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5851197P 1997-09-11 1997-09-11
US60/058,511 1997-09-11

Publications (2)

Publication Number Publication Date
WO1999012576A2 WO1999012576A2 (en) 1999-03-18
WO1999012576A3 true WO1999012576A3 (en) 1999-06-03

Family

ID=22017263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019267 WO1999012576A2 (en) 1997-09-11 1998-09-11 Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy

Country Status (2)

Country Link
AU (1) AU9487698A (en)
WO (1) WO1999012576A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007115182A2 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
MX2008012663A (en) 2006-03-30 2008-10-13 Palatin Technologies Inc Cyclic natriuretic peptide constructs.
WO2010078325A2 (en) * 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668618A (en) * 1979-11-06 1981-06-09 Green Cross Corp:The Remedy for disease related to disorder of circulatory organ consisting essentially of kallikrein of human urine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668618A (en) * 1979-11-06 1981-06-09 Green Cross Corp:The Remedy for disease related to disorder of circulatory organ consisting essentially of kallikrein of human urine

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
H. MURAKAMI ET AL: "Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats", KIDNEY INTERNATIONAL, vol. 53, 1998, pages 1305 - 1313, XP002099190 *
H. S. MARGOLIUS: "Tissue Kallikreins and Kinins: Regulation and Roles in Hypertensive and Diabetic Diseases", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 29, 1989, pages 343 - 364, XP002099188 *
J. CHAO ET AL: "Experimental Kallikrein Gene Therapy in Hypertension, Cardiovascular and Renal Diseases", PHARMACOLOGICAL RESEARCH, vol. 35, no. 6, 1997, pages 517 - 522, XP002099186 *
J. CHAO ET AL: "Human Kallikrein Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy , and Renal Injury in Dahl Salt-Sensitive Rats", HUMAN GENE THERAPY, vol. 9, 1 January 1998 (1998-01-01), pages 21 - 31, XP002099183 *
KUEI-FU LIN ET AL: "Atrial Natriuretic Peptide Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy, and Renal Injury in Salt-Sensitive Rats", HUMAN GENE THERAPY, vol. 9, 1 July 1998 (1998-07-01), pages 1429 - 1438, XP002099184 *
KUEI-FU LIN ET AL: "Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive Rats", HYPERTENSION, vol. 26, no. 6(1), December 1995 (1995-12-01), pages 847 - 853, XP002099187 *
L. JIN ET AL: "Gene Therapy in Hypertension: Adenovirus-Mediated Kallikrein Gene Delivery in Hypertensive Rats", HUMAN GENE THERAPY, vol. 8, 10 October 1997 (1997-10-10), pages 1753 - 1761, XP002099185 *
PATENT ABSTRACTS OF JAPAN vol. 5, no. 132 (C - 068) 22 August 1981 (1981-08-22) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9441027B2 (en) 2011-08-30 2016-09-13 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9587004B2 (en) 2011-08-30 2017-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides

Also Published As

Publication number Publication date
WO1999012576A2 (en) 1999-03-18
AU9487698A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
WO1997012986A3 (en) Non-group c adenoviral vectors
AU2681497A (en) Novel agouti-related gene
WO1999014346A3 (en) SENSE mRNA THERAPY
CA2257133A1 (en) Human dnase i hyperactive variants
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
WO1999006554A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
WO2001079443A3 (en) Albumin fusion proteins
WO1999006549B1 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO1999012576A3 (en) Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
WO1998040498A3 (en) Immunoadhesins and methods of production and use thereof
WO2002032415A3 (en) Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells
WO1998011234A3 (en) Human protein kinases
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
WO1998010085A3 (en) Gene therapy for congestive heart failure
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO2000063415A8 (en) Dna encoding the human vanilloid receptor vr1
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO2000029589A8 (en) Methioninase gene therapy for tumor treatment
WO2001054707A3 (en) Modification of surface proteins by aminopeptidase inhibitors
WO2001048164A3 (en) Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
WO1995034649A3 (en) Polycystic kidney disease 1 gene and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA